Ladone Mary Kay sold $98K of KMTS

Ladone Mary Kay sold 3,908 shares of KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) at $25.20 on 2026-09-08.

Original reporting
SEC EDGAR · Ladone Mary Kay
Published Sep 11, 2026, 12:25 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 11, 2026, 12:54 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$KMTS
Neutral
high confidence
Mentioned
$KMTS
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$KMTSNeutralLow
01

Why it matters

The sale represents a modest reduction in insider holdings with limited price impact.

02

Market read

Low relevance; typical insider transaction with minimal market effect.

03

What to watch

Potential upcoming corporate actions or financing needs not disclosed in the filing.

Relevance 3/10Novelty 4/10Timing: filed Sep 10, reported Sep 11

Background

Form 4 filings disclose insider trades; this filing reports a director's recent sale.

Company-level read

Ticker impact

$KMTSNeutralHigh confidence
Context

Director Ladone Mary Kay sold 3,908 shares for $98,464 on Sep 8, reducing her stake to 37,507 shares.

Expected impact

minimal impact, price likely to stay within current range

Evidence & confidence

Insider sale size is small relative to float and market cap; no immediate catalyst.

Market effects

None; the transaction is company‑specific.

None; limited to KMTS shareholders.

None

Counterpoint

If insider selling signals concerns, a short position could be considered, but evidence is weak.

Key entities

  • Ladone Mary Kay

    Director of KestrA Medical Technologies, Ltd.

  • KestrA Medical Technologies, Ltd.

    Medical device company listed on Nasdaq under KMTS.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$KMTSMedAI 8/10

Kestra study shows 100% shock conversion in wearable defibrillator

Kestra Medical Technologies (KMTS) reported 100% conversion success in its ASSURE Wearable Cardioverter Defibrillator study, meeting safety and effectiveness goals. The study, involving 21,612 patients, showed a 0.0065 inappropriate-shock rate and 94% of patients with no false alarms. The company plans an algorithm update to reduce inappropriate shocks by 70%.

$KMTSHigh

Why is Kestra Medical stock gaining today?

Kestra Medical Technologies (KMTS) stock rose 0.4% to $29.50 in pre-market trading after Evercore ISI initiated coverage with an Outperform rating and $34.00 price target. The firm cited Kestra's potential in the wearable cardioverter defibrillator market, projected 30%+ annual revenue growth, and gross margin expansion to mid-70% by 2030. The move contrasts with a mixed broader market.

$KMTSHighAI 8/10

Kestra Medical Technologies Signals Profitable Growth Path

Kestra Medical Technologies (KMTS) reported Q1 revenue of $31M, up 60% YoY, with gross margin at 56.5%, up from 45.7% YoY. The company raised 2027 revenue guidance to $141M and expects profitability within a few years. Management highlighted strong growth drivers, including market expansion and automation.